Quantcast

US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting

May 26, 2011

THE WOODLANDS, Texas, May 26, 2011 /PRNewswire/ — McKesson Specialty Care Solutions | US Oncology, a division of McKesson Corporation, announced today that four physicians affiliated with US Oncology Research and the United Network of US Oncology will give oral presentations at the 47(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 3 – 7 at McCormick Place in Chicago.

ASCO is the world’s leading professional organization representing physicians who care for people with cancer. More than 70 McKesson Specialty Care Solutions | US Oncology affiliated oncology experts have contributed to more than 60 studies being featured at this year’s major medical meeting.

“US Oncology Research affiliated investigators are consistently on the cutting edge when it comes to the life-changing therapies of the future,” said Nicholas Vogelzang, MD, oncologist at Comprehensive Cancer Centers of Nevada, co-chair of the Genitourinary Committee for US Oncology Research, and the communications chair of the 2011 ASCO Annual Meeting. “When it comes to advancing cancer care, these investigators are contributing in a major way. Take the MEK inhibitor study for example. The investigators understand molecular mechanisms, work with companies which have drugs targeting those mechanisms and use them to successfully treat patients in their practices. This is translational research at its best.”


    The four studies being presented orally at ASCO
     by US Oncology Research affiliated physicians
     are as follows:
    Frankie Ann Holmes, MD, Texas Oncology
                Sunday, June 5, 9:45 AM -10:00 AM,
                Hall B1
                Correlation of molecular effects and
                pathologic complete response to
                preoperative lapatinib and
                trastuzumab, separately and combined
                prior to neoadjuvant breast cancer
           --   chemotherapy.

    John Pippen, MD, FACP, Texas Oncology
                Sunday, June 5, 4:30 PM -4:45 PM,
                Hall B1
                Randomized, phase III study of
                adjuvant doxorubicin +
                cyclophosphamide (AC) --> docetaxel
                (T) +/- capecitabine (X), in high-
                risk EBC: Exploratory Ki-67
           --   analyses.

    Joyce O'Shaughnessy, MD, Texas Oncology
                Monday, June 6, 11:00 AM -11:15 AM,
                Hall B1
                A randomized phase III study of
                iniparib (BSI-201) in combination
                with gemcitabine/carboplatin (G/C)
                in metastatic triple-negative breast
           --   cancer (TNBC).

    Robert Jotte, MD, PhD, Rocky Mountain Cancer
     Centers
                Tuesday, June 7, 8:00 AM -8:15 AM,
                Arie Crown Theater
                Randomized phase III trial of
                amrubicin versus topotecan (Topo) as
                second-line treatment for small cell
           --   lung cancer (SCLC).

“Studies such as these are leading to advances in treating cancer,” said John Pippen, MD, FACP, Texas Oncology. “Our US Oncology clinical trials lead to approval of new drugs, better treatment combinations, and better prediction of whether a patient will benefit from a particular cancer treatment.”

In addition to these oral presentations, Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology, will be speaking during an education session on the management of unique subsets of patients with renal cell cancer. This session takes place on Sunday, June 5 in Hall D2 from 11:30 AM – 12:45 PM.

US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 43 FDA approved cancer fighting therapies.

Other presentations that McKesson Specialty Care Solutions | US Oncology affiliated investigators are part of include:


    Oral Presentations:
    -------------------
    Thomas Cartwright, MD, Ocala Oncology Center
                 Saturday, June 4, 2:45 PM - 3:00 PM,
                 Hall D1
                 A multinational, randomized phase III
                 study of bevacizumab (Bev) with
                 FOLFOX4 or XELOX versus FOLFOX4 alone
                 as adjuvant treatment for colon
                 cancer (CC): Subgroup analyses from
            --   the AVANT trial.

    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
                 Saturday, June 4, 4:00 PM - 4:15 PM,
                 Arie Crown Theater
                 BRIM-2: An open-label, multicenter
                 phase II study of RG7204 (PLX4032) in
                 previously treated patients with BRAF
                 V600E mutation-positive metastatic
            --   melanoma.

    Michael Teneriello, MD, FACOG, Texas Oncology
                 Saturday, June 4, 4:15 PM -4:30 PM,
                 E354a
                 OCEANS: A randomized, double-blinded,
                 placebo-controlled, phase III trial
                 of chemotherapy with or without
                 bevacizumab (BEV) in patients with
                 platinum-sensitive recurrent
                 epithelial ovarian (EOC), primary
                 peritoneal (PPC), or fallopian tube
            --   cancer (FTC).

    Jerome Goldschmidt, MD, Blue Ridge Cancer Care
                 Sunday, June 5, 10:00 AM -10:15 AM,
                 Hall D1
                 Final efficacy results from OAM4558g,
                 a randomized Phase II study
                 evaluating MetMAb or placebo in
                 combination with Erlotinib in
            --   advanced NSCLC.

    Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale
     Healthcare, US Oncology Research
                 Sunday, June 5, 11:00 AM -11:15 AM,
                 Arie Crown Theater
                 Safety, pharmacokinetics, and
                 pharmacodynamics results from a phase
                 I trial of BAY 86-9766 (RDEA119), a
                 MEK inhibitor, in patients with
            --   advanced cancer.

    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
                 Sunday, June 5, 11:50 AM -12:10 PM,
                 Hall D2
                 Management of Unique Subsets of
            --   Patients with Renal Cell Cancer.

    Nicholas Vogelzang, MD, Comprehensive Cancer
     Centers of Nevada
    Alexander Spira, MD, Virginia Cancer Specialists
                 Sunday, June 5, 12:00 PM -12:15 PM,
                 Arie Crown Theater
                 Cabozantinib (XL184) has activity in
                 both soft tissue & bone: Results of a
                 phase 2 randomized discontinuation
                 trial (RDT) in patients (pts) w/
            --   advanced solid tumors.

    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
                 Monday, June 6, 8:00 AM -8:15 AM,
                 Hall D2
                 Axitinib versus sorafenib as second-
                 line therapy for metastatic renal
                 cell carcinoma (mRCC): Results of
            --   phase III AXIS trial.

    Jeff Sharman, MD, Willamette Valley Cancer
     Institute and Research Center
    Donald Richards, MD, PhD, Texas Oncology
                 Monday, June 6, 9:30 AM -12:30 PM,
                 Arie Crown Theater
                 Activity and tolerability of the
                 Bruton's tyrosine kinase (Btk)
                 inhibitor PCI-32765 in patients with
                 chronic lymphocytic leukemia/small
                 lymphocytic lymphoma (CLL/SLL):
                 Interim results of a phase Ib/II
            --   study.

    Alexander Spira, MD, Virginia Cancer Specialists
    Nicholas Vogelzang, MD, Comprehensive Cancer
     Centers of Nevada
                 Monday, June 6, 1:15 PM -1:30 PM,
                 Hall D1
                 Cabozantinib (XL184) in metastatic
                 castration-resistant prostate cancer
                 (mCRPC): Results from a phase II
            --   randomized discontinuation trial.


    Poster Discussions:
    -------------------
    Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale
     Healthcare, US Oncology Research
                              Saturday, June 4, 8:00 AM
               Poster #23     - 12:00 PM, S403
               Discussion    12:00 PM - 1:00 PM, S406
                Phase I clinical trial of VTX-2337,
                a selective toll-like receptor 8
                (TLR8) agonist, in patients with
           --   advanced solid tumors.

    Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale
     Healthcare, US Oncology Research
                              Saturday, June 4, 2:00 PM
               Poster #5      -6:00 PM, S403
               Discussion    5:00 PM - 6:00 PM, S406
                Phase I study of the multikinase
                prodrug SF1126 in solid tumors and
           --   B-cell malignancies.

    Guru Sonpavde, MD, Texas Oncology
    Mark Fleming, MD, Virginia Oncology Associates
    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
                              Saturday, June 4, 2:00 PM
               Poster #8      -6:00 PM, E450a
               Discussion    5:00 PM - 6:00 PM, Hall D
                A randomized, double-blind phase II
                trial of docetaxel plus prednisone
                (DP) combined with either AT-101 or
                placebo for the first-line therapy
                of metastatic castration-resistant
           --   prostate cancer (CRPC).

    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
                              Saturday, June 4, 2:00 PM
               Poster #17     -6:00 PM, S103
               Discussion    5:00 PM - 6:00 PM, S100bc
                Circulating protein biomarkers of
                sunitinib and interferon efficacy in
                treatment naive patients with
           --   metastatic renal cell carcinoma.

    Carlos Becerra, MD, Texas Oncology
                              Monday, June 6, 8:00 AM -
               Poster #14     12:00 PM, E450b
                              11:30 AM -12:30 PM, Hall
               Discussion     D1
                Phase II trial of figitumumab in
                patients with refractory, metastatic
           --   colorectal cancer (mCRC).

    Donald Richards, MD, PhD, Texas Oncology
    Darren M Kocs, MD, Texas Oncology
    Alexander Spira, MD, Virginia Cancer
     Specialists
    David McCollum, MD, Texas Oncology
    Kristi Boehm, Feng Zhan, PhD, Lina Asmar, PhD,
     US Oncology Research
                              Monday, June 6, 2:00 PM -
               Poster #8      6:00 PM, E450b
                              5:00 PM -6:00 PM, Hall
               Discussion     D1
                Results of docetaxel plus oxaliplatin
                (DOCOX) +/-cetuximab in patients
                with metastatic gastric and/or
                gastroesophagel junction
                adenocarcinoma; results of a
           --   randomized phase II study.

    Donald Richards, MD, PhD, Texas Oncology
                              Monday, June 6, 2:00 PM -
               Poster #11     6:00 PM, E450b
                              5:00 PM -6:00 PM, Hall
               Discussion     D1
                Randomized phase II study (GATE
                study) of docetaxel plus oxaliplatin
                with or without fluorouracil or
                capecitabine in metastatic or
           --   locally recurrent gastric cancer.

    Guru Sonpavde, MD, Texas Oncology
    Nicholas Vogelzang, MD, Comprehensive Cancer
     Centers of Nevada
    Peter Rosen, MD, Roy & Patricia Disney Cancer
     Research Center
    Alexander Spira, MD, Virginia Cancer
     Specialists
                              Tuesday, June 7, 8:00 AM
               Poster #22     -12:00 PM, E450b
                              11:30 AM -12:30 PM,
               Discussion     E354a
                Clinical outcome of single agent
                volasertib (BI 6727) as second-line
                treatment of patients (pts) with
                advanced or metastatic urothelial
           --   cancer (UC).


    Posters:
    --------
    Joyce O'Shaughnessy, MD, Texas Oncology
    Thomas Cartwright, MD, Ocala Oncology Center
                              Saturday, June 4, 8:00 AM
               Poster #21C    -12:00 PM, Hall A
                Effect of dose modification on the
                efficacy of capecitabine: Data from
                six randomized, phase III trials in
                patients with colorectal or breast
           --   cancer.

    Joe Stephenson, MD, Cancer Centers of the
     Carolinas
    Donald Richards, MD, PhD, Texas Oncology
    Carlos Becerra, MD, Texas Oncology
                              Saturday, June 4, 8:00 AM
               Poster #36H    -12:00 PM, Hall A
                The safety of IPI-926, a novel
                hedgehog pathway inhibitor, in
                combination with gemcitabine in
                patients (pts) with metastatic
           --   pancreatic cancer.

    Nicholas Robert, MD, Virginia Cancer
     Specialists
                              Saturday, June 4, 8:00 AM
               Poster #43C    -12:00 PM, Hall A
                Utilization and clinical practice
                impact of an interactive tool for
                guiding choice of systemic adjuvant
                treatment (adj TX) for patients with
           --   early breast cancer (EBC).

    Craig Reynolds, MD, Ocala Oncology Center
    Alexander Spira, MD, Virginia Cancer
     Specialists
    Larry Gluck, MD, Cancer Centers of the
     Carolinas
    Robert Pluenneke, MD, Kansas City Cancer
     Centers
    Kristi Boehm, Feng Zhan, PhD, Lina Asmar, PhD,
     US Oncology Research
                              Saturday, June 4, 2:00 PM
               Poster #33E    -6:00 PM, Hall A
                Results of a phase II study of
                single-agent sunitinib in elderly
                non-small cell lung cancer
           --   patients.

    Ruth Oratz, MD, FACP, The Women's Oncology &
     Wellness Practice
                              Saturday, June 4, 2:00 PM
               Poster #1B     -6:00 PM, Hall A
                Recruitment in the internet era: An
                efficient strategy for studying
           --   breast cancer risk.

    Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale
     Healthcare, US Oncology Research
                              Sunday, June 5, 8:00 AM -
               Poster #9F     12:00 PM, Hall A
                A phase I dose escalation study of
                NKP-1339 in patients with advanced
                solid tumors refractory to
           --   treatment.

    William Berry, MD, Cancer Centers of North
     Carolina
    Guru Sonpavde, MD, Texas Oncology
                              Sunday, June 5, 8:00 AM -
               Poster #2E     12:00 PM, Hall A
                Evaluating the value of continuing
                docetaxel and prednisone (DP) beyond
                10 cycles in men with metastatic
                castration-resistant prostate
           --   cancer (mCRPC).

    Guru Sonpavde, MD, Texas Oncology
                              Sunday, June 5, 8:00 AM -
               Poster #2F     12:00 PM, Hall A
                Association of progression-free
                survival (PFS) at 2 or 3 years with
                overall survival (OS) at 5 years for
                locally advanced bladder cancer
                (BC): Evaluation of individual
                patient data (IPD) from seven
                randomized trials comparing local
                therapy with or without neoadjuvant
           --   chemotherapy (NC).

    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
                              Sunday, June 5, 8:00 AM -
               Poster #5D     12:00 PM, Hall A
                A pooled analysis of the efficacy and
                safety of sunitinib in elderly
                patients with metastatic renal cell
           --   carcinoma.

    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
                              Sunday, June 5, 8:00 AM -
               Poster #6B     12:00 PM, Hall A
                Analysis of the relationship between
                KPS and tumor response in the
                RECORD-1 phase III trial of
                everolimus in patients with advanced
           --   renal cell carcinoma.

    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
                              Sunday, June 5, 8:00 AM -
               Poster #9A     12:00 PM, Hall A
                Very low incidence of thyroid
                dysfunction in renal cell carcinoma
                patiens treated with pazopanib in
           --   prospective clinical trials.

    Guru Sonpavde, MD, Texas Oncology
                              Sunday, June 5, 8:00 AM -
               Poster #13F    12:00 PM, Hall A
                Results of a phase I/II clinical
                trial of BPX-101, a novel drug-
                activated dendritic cell (DC)
                vaccine for metastatic castration-
           --   resistant prostate cancer (mCRPC).

    Michael Teneriello, MD, FACOG, Texas Oncology
    John R. Caton, MD, Willamette Valley Cancer
     Institute and Research Center
    Robert H. Gersh, MD, Cancer Care Northwest
                              Sunday, June 5, 8:00 AM -
               Poster #15A    12:00 PM, Hall A
                PRECEDENT: A randomized phase II
                trial comparing EC145 and pegylated
                liposomal doxorubicin (PLD) in
                combination, versus PLD alone, in
                subjects with platinum-resistant
           --   ovarian cancer.

    Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale
     Healthcare, US Oncology Research
                              Monday, June 6, 8:00 AM -
               Poster #16A    12:00 PM, Hall A
                First in human study with ARQ 621, a
                novel inhibitor of Eg5: final
                results from the solid tumors
           --   cohort.

    Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale
     Healthcare, US Oncology Research
                              Monday, June 6, 8:00 AM -
               Poster #17D    12:00 PM, Hall A
                Findings from the phase I clinical
                trials of CX-4945, an orally
           --   available inhibitor of CK2.

    Stephen Anthony, DO, Evergreen Hematology and
     Oncology
    Daniel D. Von Hoff, MD, FACP, TGen, Scottsdale
     Healthcare, US Oncology Research
                              Monday, June 6, 8:00 AM -
               Poster #18B    12:00 PM, Hall A
                Pharmacodynamic activity demonstrated
                in phase I for PLX3397, a selective
           --   inhibitor of FMS and Kit.

    Kavita Sail, MS, PhD, Healthcare Informatics,
     US Oncology
    Melissa Halm, MPH, Healthcare Informatics, US
     Oncology
    Debra Patt, MD, MPH, Texas Oncology
                              Monday, June 6, 1:00 PM -
               Poster #12B    5:00 PM, Hall A
                Treatment patterns in patients with
                HER2-positive early-stage breast
                cancer (ESBC) receiving adjuvant
                treatment with a trastuzumab-
           --   containing regimen.

    Clara Chen, MS, Healthcare Informatics, US
     Oncology
    Debra Patt, MD, MPH, Texas Oncology
    Michael Forsyth, RPh, MBA, Rocky Mountain
     Cancer Centers
    Denise Kazzaz, Jeff Shankleton, Ramachandran
     Ganesh, Healthcare Informatics, US Oncology
                              Monday, June 6, 1:00 PM -
               Poster #12C    5:00 PM, Hall A
                Evaluating utilization
                characteristics for the Oncotype DX
                recurrence score in early-stage
           --   breast cancer.

    Nicholas Robert, MD, Virginia Cancer
     Specialists
    Joyce O'Shaughnessy, MD, Texas Oncology
                              Monday, June 6, 1:00 PM -
               Poster #19E    5:00 PM, Hall A
                Capecitabine (X) in the first-line
                treatment of metastatic breast
           --   cancer (MBC).

    Karen Tedesco, MD, New York Oncology
     Hematology
    Joanne Blum, MD, Texas Oncology
    Cynthia Osborne, MD, Texas Oncology
    Frankie Ann Holmes, MD, Texas Oncology
                              Monday, June 6, 1:00 PM -
               Poster #25B    5:00 PM, Hall A
                Final results of a phase II trial of
                trabectedin (T) in triple-negative,
                HER2-positive and BRCA1/2 germ-
                line-mutated metastatic breast
           --   cancer (MBC) patients (pts).

    Robert Rifkin, MD, FACP, Rocky Mountain Cancer
     Centers
                              Monday, June 6, 1:00 PM -
               Poster #48D    5:00 PM, Hall A
                Impact of baseline characteristics on
                efficacy and safety after
                bortezomib-based induction and
                maintenance in newly diagnosed
                multiple myeloma patients ineligible
                for transplant in the phase 3b
           --   UPFRONT study.


    Trials in Progress:
    -------------------
    Joanne Blum, MD, Texas Oncology
                Poster      Monday, June 6, 8:00 AM -
                #37D        12:00 PM, Hall A
                A phase II study of ridaforolimus
                (RIDA) and dalotuzumab (DALO) in
                estrogen receptor positive-(ER+)
           --   breast cancer.

    Allen Cohn, MD, Rocky Mountain Cancer
     Centers
    Linda DeMarco, MD, FACP, New York Oncology
     Hematology
    Jean Stephenson, RN, Texas Oncology
    Brian Ulrich, MD, Texas Oncology
    Peter Yu, MD, Camino Medical Group
                Poster      Monday, June 6, 8:00 AM -
                #45F        12:00 PM, Hall A
                Randomized phase II study of the
                efficacy and safety of gemcitabine
                + TH-302 vs gemcitabine alone in
                previously untreated patients with
           --   advanced pancreatic cancer.

    Frankie Ann Holmes, MD, Texas Oncology
                Poster      Monday, June 6, 8:00 AM -
                #40G        12:00 PM, Hall A
                A phase 3 trial of adjuvant
                neratinib (NER) after trastuzumab
                (TRAS) in women with early-stage
           --   HER2+ breast cancer (BC).

    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
                Poster      Monday, June 6, 8:00 AM -
                #47H        12:00 PM, Hall A
                Phase I/II study of BNC105P in
                combination with everolimus or
                following everolimus for
                progressive metastatic renal cell
                carcinoma following prior tyrosine
           --   kinase inhibitors.


    Publish Only:
    -------------
    Joyce O'Shaughnessy, MD, Texas Oncology
                Eribulin mesylate EMBRACE study:
                Survival analysis excluding patients
                rechallenged with therapies of the
    --          same class.

    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
                Phase III study of axitinib versus
                sorafenib for treatment of patients
                with metastatic renal cell carcinoma.
    --           TRIAL in PROGRESS.

    William Berry, MD, Cancer Centers of North
     Carolina
    Mark Fleming, MD, Virginia Oncology Associates
    Michael Kolodziej, MD, New York Oncology
     Hematology
    Sanjiv Awasthi, Texas Oncology
    Thomas E. Hutson, DO, PharmD, FACP, Texas
     Oncology
    Danko Martincic, MD, Cancer Care Northwest
    Guru Sonpavde, MD, Texas Oncology
    Yunfei Wang, Lina Asmar, PhD, US Oncology
     Research
                Association of rash with improved
                outcomes by the addition of cetuximab
                (C) to second-line mitoxantrone plus
                prednisone (MP) for progressive mCRPC
    --          after docetaxel-based chemotherapy.

    Nicholas Vogelzang, MD, Comprehensive Cancer
     Centers of Nevada
    Paul Conkling, MD, Virginia Oncology Associates
    Manuel Modiano, MD, Arizona Oncology Associates
                An open-label, multicenter,
                randomized Phase Ib/II study of
                eribulin mesylate administered in
                combination with gemcitabine plus
                cisplatin versus gemcitabine plus
                cisplatin alone as first line therapy
                for locally advanced or metastatic
    --          bladder cancer.

    Marcus Neubauer, MD, Jody S. Garey, PharmD,
     Greg Nelson, Debra Patt, MD, Tom Cartwright,
     MD, Russ Hoverman, MD, Leslie T. Busby, MD,
     Barry Brooks, MD, Mark Sitarik, MD, Mike
     Kolodziej, MD, Roger Anderson Dr PH, Roy
     Beveridge, MD; on behalf of the US Oncology
     Pathways Task Force and Clinical Content
     Development Team
                Bevacizumab therapy in advanced non-
                small cell lung cancer (NSCLC):
                outcomes from a community oncology
    --          network.

    Mark Fleming, MD, Virginia Oncology Associates
    John Burke, MD, Rocky Mountain Cancer Centers
    John R. Caton, MD, Willamette Valley Cancer
     Institute and Research Center
    Guru Sonpavde, MD, Texas Oncology
                Ability of serum alkaline phosphatase
                (ALP) changes to complement PSA
                changes and predict survival in men
                with metastatic castration-resistant
                prostate cancer (mCRPC) receiving
    --          docetaxel and prednisone (DP).

    Aimee L. Ginsburg, PharmD, Debra M. Patt MD,
     Jennifer Flinn, Janet L. Espirito, PharmD,
     Marcus A. Neubauer, MD, J. Russell Hoverman,
     MD, PhD, Thomas H. Cartwright, MD, Leslie T.
     Busby, MD, Barry Don Brooks, MD, Michael A.
     Kolodziej, MD, Mark A. Sitarik, MD; on behalf
     of the US Oncology Pathways Task Force and
     Clinical Content Development Team
                Understanding Male Breast Cancer in
    --          the Community Setting.

    Debra Patt, MD, Janet Espirito, PharmD, Brian
     Turnwald, J. Russell Hoverman, MD, Marcus
     Neubauer, MD, Thomas Cartwright, MD, Barry
     Brooks, MD, Leslie Busby, MD, Mark Sitarik,
     MD, Michael Kolodziej, MD, Aimee Ginsburg,
     PharmD, Sheetal Sheth, PharmD, Jody Garey,
     PharmD, Matthew Clayton, Greg Nelson, Roger
     Anderson, DrPH, Roy Beveridge, MD; on behalf
     of the US Oncology Pathways Task Force and
     Clinical Content Development Team
                Utilization and relative value of
                breast cancer adjuvant chemotherapy
    --          regimens in the community.

    Avani Joshi, PhD, Healthcare Informatics, US
     Oncology
    David Fryefield, MD, Willamette Valley Cancer
     Institute and Research Center
    Michael Forsyth, RPh, MBA, Rocky Mountain
     Cancer Centers
    William Lopez, Healthcare Informatics, US
     Oncology
                Demographic and treatment
                characteristics for advanced basal
                cell carcinoma (aBCC) in an oncology
    --          outpatient setting.

    Thomas Cartwright, MD, Ocala Oncology Center
    Michael Forsyth, RPh, MBA, Rocky Mountain
     Cancer Centers
    Heather Hartnett, PhD, Hsingwen Chung, MS,
     Melissa Halm, MPH, Healthcare Informatics, US
     Oncology
                mCRC -Survival Outcomes with the use
                of Bevacizumab beyond progression in
                metastatic colorectal cancer
    --          patients.

    Clara Chen, MS, Healthcare Informatics, US
     Oncology
    Debra Patt, MD, MPH, Texas Oncology
    Michael Forsyth, RPh, MBA, Rocky Mountain
     Cancer Centers
    Denise Kazzaz, Jeff Shankleton, Ramachandran
     Ganesh, Healthcare Informatics, US Oncology
                Evaluation of relation between
                Oncotype DX recurrence score and
    --          adjuvant chemotherapy administration.

    Kavita Sail, MS, PhD, Healthcare Informatics,
     US Oncology
    Debra Patt, MD, MPH, Texas Oncology
    Michael Forsyth, RPh, MBA, Rocky Mountain
     Cancer Centers
    Melissa Halm, MPH, William Lopez, Healthcare
     Informatics, US Oncology
                Patterns of Care and Patient
                Characteristics in Post-menopausal
                Women with HER2+ and Hormone Receptor
                Positive (HR+) Metastatic Breast
    --          Cancer (MBC).

    Dean Gesme, MD, FACP, FACPE, Minnesota Oncology
                Risk of treatment failure after first-
                line tyrosine kinase inhibitors (TKI)
                therapy in patients with metastatic
    --          renal cell carcinoma.

    Joanne Blum, MD, Texas Oncology
                Capecitabine (Cap) monotherapy in
                anthracycline (A)-/taxane - (T)
    --          pretreated MBC.


    Presentations from McKesson:
    ----------------------------

    Poster:
    -------
    Zhaohui Wang, McKesson Specialty Care
     Solutions
                  Poster      Saturday, June 4, 2:00 PM
                  #32B        - 6:00 PM, Hall A
                  Guideline adherence rates and costs
                  of chemotherapy treatment for
                  NSCLC patients treated in U.S.
             --   community oncology practices.

    Publish Only:
    -------------
    Brandon Tom, McKesson Corporation
                  Leveraging technology and data to
                  facilitate development of cost-
    --            effective pathways.

About McKesson Specialty Care Solutions | US Oncology

McKesson Specialty Care Solutions | US Oncology, a division of McKesson Corporation, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our customers and help them provide quality care for patients. For more information, visit www.mckesson.com/specialty and www.usoncology.com.

About US Oncology Research

McKesson Specialty Care Solutions | US Oncology conducts clinical research through US Oncology Research, its wholly-owned subsidiary uniting one of the nation’s largest community-based cancer research networks. US Oncology Research has experienced investigators and dedicated research nurses who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 95 sites in 225 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 48,000 patients in more than 1,150 trials since inception in 1992 and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (866) 216-5053 or visit www.usoncology.com/oncologists.

About Healthcare Informatics

McKesson Specialty Care Solutions | US Oncology integrates oncology expertise and business insight through its Healthcare Informatics program to provide real-world, evidence-based market intelligence for managing a drug therapy’s lifecycle. Comprehensive cancer care data assets such as electronic health records (EHRs), claims, specialties, reimbursement, and sales data provide unparalleled insight into the oncology marketplace to drive and develop successful commercialization strategies. The Healthcare Informatics group includes outcomes researchers, clinical data analysts, pharmacists, and biostatisticians who provide clinical and economic expertise to guide strategic branding and business decisions for the oncology industry. For more information, please call (866) 951-2774 or email bpsg@usoncology.com.

SOURCE US Oncology, Inc.


Source: newswire



comments powered by Disqus